Inter-assay variability in automated serum free light chain assays and their use in the clinical laboratory

References

• Liu H, May K. Disulfide bond structures of IgG molecules: structural variations, chemical modifications and possible impacts to stability and biological function. MAbs. 2012;4(1):17–23.
   PubMed Web of Science ®Google Scholar
• Solomon A. Light chains of immunoglobulins: structural-genetic correlates. Blood. 1986;68(3):603–610.
   PubMed Web of Science ®Google Scholar
• Ghanem N, Dariavach P, Bensmana M, et al. Polymorphism of immunoglobulin lambda constant region genes in populations from France, Lebanon and Tunisia. Exp Clin Immunogenet. 1988;5(4):186–195.
   PubMedGoogle Scholar
• Jefferis R, Lefranc M-P. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 2009;1(4):332–338.
   PubMed Web of Science ®Google Scholar
• Köhler G. Immunoglobulin chain loss in hybridoma lines. Proc Natl Acad Sci USA. 1980;77(4):2197–2199.
   PubMed Web of Science ®Google Scholar
• Solomon A. Light chains of human immunoglobulins. Meth Enzymol. 1985;116:101–121.
   PubMed Web of Science ®Google Scholar
• Leitzgen K, Knittler MR, Haas IG. Assembly of immunoglobulin light chains as a prerequisite for secretion. A model for oligomerization-dependent subunit folding. J Biol Chem. 1997;272(5):3117–3123.
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Strober W, Mogielnicki RP. The renal handling of low molecular weight proteins. II. Disorders of serum protein catabolism in patients with tubular proteinuria, the nephrotic syndrome, or uremia. J Clin Invest. 1972;51(8):2162–2174.
   PubMed Web of Science ®Google Scholar
• Berggård I, Peterson PA. Polymeric forms of free normal kappa and lambda chains of human immunoglobulin. J Biol Chem. 1969;244(16):4299–4307.
   PubMed Web of Science ®Google Scholar
• Sölling K. Polymeric forms of free light chains in serum from normal individuals and from patients with renal diseases. Scand J Clin Lab Invest. 1976;36(5):447–452.
   PubMed Web of Science ®Google Scholar
• Sølling K. Light chain polymerism in normal individuals in patients with severe proteinuria and in normals with inhibited tubular protein reabsorption by lysine. Scand J Clin Lab Invest. 1980;40(2):129–134.
   PubMed Web of Science ®Google Scholar
• Abraham RS, Charlesworth MC, Owen BAL, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem. 2002;48(10):1805–1811.
   PubMed Web of Science ®Google Scholar
• Stevens FJ, Schiffer M. Structure and properties of human immunoglobulin light-chain dimers. Methods Mol Biol. 1995;51:51–81.
   PubMedGoogle Scholar
• Kaplan B, Livneh A, Sela B-A. Immunoglobulin free light chain dimers in human diseases. ScientificWorldJ. 2011;11:726–735.
   PubMedGoogle Scholar
• Rennella E, Morgan GJ, Kelly JW, et al. Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proc Natl Acad Sci USA. 2019;116(3):854–863.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Cockwell P, Reid S, et al. Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies. J Am Soc Nephrol. 2007;18(3):886–895.
   PubMed Web of Science ®Google Scholar
• Basnayake K, Stringer SJ, Hutchison CA, et al. The biology of immunoglobulin free light chains and kidney injury. Kidney Int. 2011;79(12):1289–1301.
   PubMed Web of Science ®Google Scholar
• Solomon A, Waldmann TA, Fahey JL, et al. Metabolism of Bence Jones proteins. J Clin Invest. 1964;43:103–117.
   PubMed Web of Science ®Google Scholar
• Maack T, Johnson V, Kau ST, et al. Renal filtration, transport, and metabolism of low-molecular-weight proteins: a review. Kidney Int. 1979;16(3):251–270.
   PubMed Web of Science ®Google Scholar
• Camargo MJ, Sumpio BE, Maack T. Kinetics of renal catabolism of absorbed proteins: influence of lysosomal pH. Contrib Nephrol. 1984;42:19–29.
   PubMedGoogle Scholar
• Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48(9):1437–1444.
   PubMed Web of Science ®Google Scholar
• Te Velthuis H, Knop I, Stam P, et al. N Latex FLC – new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med. 2011;49(8):1323–1332.
   PubMed Web of Science ®Google Scholar
• Cotten SW, Shajani-Yi Z, Cervinski MA, et al. Reference intervals and diagnostic ranges for serum free κ and free λ immunoglobulin light chains vary by instrument platform: implications for classification of patient results in a multi-center study. Clin Biochem. 2018;58:100–107.
   PubMed Web of Science ®Google Scholar
• Lutteri L, Jacobs J. Reference ranges of the Sebia free light chain ratio in patients with chronic kidney disease. Clin Chem Lab Med. 2018;56(9):e232–e234.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–548.
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–757.
   PubMed Web of Science ®Google Scholar
• Dejoie T, Attal M, Moreau P, et al. Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma. Haematologica. 2016;101(3):356–362.
   PubMed Web of Science ®Google Scholar
• Katzmann JA. Screening panels for monoclonal gammopathies: time to change. Clin Biochem Rev. 2009;30(3):105–111.
   PubMedGoogle Scholar
• Dispenzieri A, Kyle R, Merlini G, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009;23(2):215–224.
   PubMed Web of Science ®Google Scholar
• Palladini G, Russo P, Bosoni T, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem. 2009;55(3):499–504.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Katzmann JA, Kyle RA, et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet. 2010;375(9727):1721–1728.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Durie BGM, Rajkumar SV, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–1127.
   PubMed Web of Science ®Google Scholar
• Larsen JT, Kumar SK, Dispenzieri A, et al. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia. 2013;27(4):941–946.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Katzmann JA, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–789.
   PubMed Web of Science ®Google Scholar
• Lakshman A, Rajkumar SV, Buadi FK, et al. Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria. Blood Cancer J. 2018;8(6):59.
   PubMedGoogle Scholar
• Wu V, Moshier E, Leng S, et al. Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling. Blood Adv. 2018;2(12):1470–1479.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau J-L, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117(18):4691–4695.
   PubMed Web of Science ®Google Scholar
• Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3–9.
   PubMed Web of Science ®Google Scholar
• Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328–e346.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Plant T, Drayson M, et al. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. BMC Nephrol. 2008;9(1):11.
   PubMedGoogle Scholar
• Merlini G, Dispenzieri A, Sanchorawala V, et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018;4(1):38.
   PubMed Web of Science ®Google Scholar
• Brenner DA, Jain M, Pimentel DR, et al. Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 2004;94(8):1008–1010.
   PubMed Web of Science ®Google Scholar
• Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation. 2001;104(14):1594–1597.
   PubMed Web of Science ®Google Scholar
• McWilliams-Koeppen HP, Foster JS, Hackenbrack N, et al. Light chain amyloid fibrils cause metabolic dysfunction in human cardiomyocytes. PLoS One. 2015;10(9):e0137716.
   PubMed Web of Science ®Google Scholar
• Mishra S, Guan J, Plovie E, et al. Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol. 2013;305(1):H95–H103.
   PubMed Web of Science ®Google Scholar
• Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci USA. 2010;107(9):4188–4193.
   PubMed Web of Science ®Google Scholar
• Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159–168.
   PubMed Web of Science ®Google Scholar
• Chang IC, Dispenzieri A, Scott CG, et al. Utility of the serum free light chain assay in the diagnosis of light chain amyloidosis in patients with heart failure. Mayo Clin Proc. 2019;94(3):447–454.
   PubMed Web of Science ®Google Scholar
• Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012;30(36):4541–4549.
   PubMed Web of Science ®Google Scholar
• Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325–2332.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood. 2006;107(8):3378–3383.
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122(1):78–84.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Katzmann JA, et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood. 2010;116(24):5126–5129.
   PubMed Web of Science ®Google Scholar
• Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012;30(9):989–995.
   PubMed Web of Science ®Google Scholar
• Sidana S, Tandon N, Gertz MA, et al. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis. Br J Haematol. 2019;185(4):701–707.
   PubMed Web of Science ®Google Scholar
• Li T, Huang X, Wang Q, et al. A risk stratification for systemic immunoglobulin light-chain amyloidosis with renal involvement. Br J Haematol. 2019. DOI:https://doi.org/10.1111/bjh.16112
   Google Scholar
• Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia. 2018;32(9):1883–1898.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Landau H, Comenzo RL, et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol. 2016;34(10):1097–1103.
   PubMed Web of Science ®Google Scholar
• Wechalekar AD, Whelan C. Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis. Blood Cancer J. 2017;7(3):e546.
   PubMedGoogle Scholar
• Bradwell AR, Carr-Smith HD, Mead GP, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem. 2001;47(4):673–680.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, de Kat Angelino CM, Brouwers H, et al. Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods. Clin Chem Lab Med. 2018;56(2):312–322.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Hoedemakers RMJ, Teunissen E, et al. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta. 2012;413(19-20):1708–1709.
   PubMed Web of Science ®Google Scholar
• Jenner E, Levoguer A, Evans J, et al. Serum free light chain immunoassays: a guide to antigen excess detection. Clin Chim Acta. 2012;413(9-10):949.
   PubMed Web of Science ®Google Scholar
• Vercammen MJ, Broodtaerts L, Meirlaen P, et al. Overestimation of free light chain antigen excess rate. Clin Chim Acta. 2015;444:297–302.
   PubMed Web of Science ®Google Scholar
• Lutteri L, Aldenhoff M-C, Cavalier E. Evaluation of the new Sebia free light chain assay using the AP22 ELITE instrument. Clin Chim Acta. 2018;487:161–167.
   PubMed Web of Science ®Google Scholar
• Smith A, Wu A. Analytical and clinical concordance of free light chain assay. Pract Lab Med. 2019;13:e00112.
   PubMedGoogle Scholar
• Campbell JP, Cobbold M, Wang Y, et al. Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods. 2013;391(1-2):1–13.
   PubMed Web of Science ®Google Scholar
• Campbell JP, Heaney JLJ, Shemar M, et al. Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool. Clin Chem Lab Med. 2017;55(3):424–434.
   PubMed Web of Science ®Google Scholar
• Tate J, Bazeley S, Sykes S, et al. Quantitative serum free light chain assay–analytical issues. Clin Biochem Rev. 2009;30(3):131–140.
   PubMedGoogle Scholar
• Carr-Smith HD, Jenner EL, Evans JAR, et al. Analytical issues of serum free light chain assays and the relative performance of polyclonal and monoclonal based reagents. Clin Chem Lab Med. 2016;54(6):997–1003.
   PubMed Web of Science ®Google Scholar
• Briand P-Y, Decaux O, Caillon H, et al. Analytical performance of the serum free light chain assay. Clin Chem Lab Med. 2010;48(1):73–79.
   PubMed Web of Science ®Google Scholar
• Tate JR, Mollee P, Dimeski G, et al. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta. 2007;376(1-2):30–36.
   PubMed Web of Science ®Google Scholar
• Vercammen M, Meirlaen P, Broodtaerts L, et al. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta. 2011;412(19-20):1798–1804.
   PubMed Web of Science ®Google Scholar
• Bosmann M, Kössler J, Stolz H, et al. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med. 2010;48(10):1419–1422.
   PubMed Web of Science ®Google Scholar
• Altinier S, Seguso M, Zaninotto M, et al. Serum free light chain reference values: a critical approach. Clin Biochem. 2013;46(7-8):691–693.
   PubMed Web of Science ®Google Scholar
• Caponi L, Koni E, Romiti N, et al. Different immunoreactivity of monomers and dimers makes automated free light chains assays not equivalent. Clin Chem Lab Med. 2018;57(2):221–229.
   PubMed Web of Science ®Google Scholar
• Lock RJ, Saleem R, Roberts EG, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem. 2013;50(3):255–261.
   PubMed Web of Science ®Google Scholar
• Graziani MS. Measurement of free light chains – pros and cons of current methods. Clin Chem Lab Med. 2016;54(6):1015–1020.
   PubMed Web of Science ®Google Scholar
• Te Velthuis H, Drayson M, Campbell JP. Measurement of free light chains with assays based on monoclonal antibodies. Clin Chem Lab Med. 2016;54(6):1005–1014.
   PubMed Web of Science ®Google Scholar
• Hoedemakers RMJ, Pruijt JFM, Hol S, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med. 2011;50(3):489–495.
   PubMedGoogle Scholar
• Kim H-S, Kim HS, Shin K-S, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. Biomed Res Int. 2014;2014:742762.
   Web of Science ®Google Scholar
• Palladini G, Jaccard A, Milani P, et al. Circulating free light chain measurement in the diagnosis, prognostic assessment and evaluation of response of AL amyloidosis: comparison of Freelite and N latex FLC assays. Clin Chem Lab Med. 2017;55(11):1734–1743.
   PubMed Web of Science ®Google Scholar
• Mahmood S, Wassef NL, Salter SJ, et al. Comparison of free light chain assays: freelite and N latex in diagnosis, monitoring, and predicting survival in light chain amyloidosis. Am J Clin Pathol. 2016;146(1):78–85.
   PubMed Web of Science ®Google Scholar
• Messiaen A-S, De Sloovere MMW, Claus P-E, et al. Performance evaluation of serum free light chain analysis: nephelometry vs turbidimetry, monoclonal vs polyclonal reagents. Am J Clin Pathol. 2017;147(6):611–622.
   PubMed Web of Science ®Google Scholar
• White-Al Habeeb NMA, Earle T, Spencer M, et al. Evaluation of the N-latex serum free light chain assay on the Siemens BNII analyzer and agreement with The Binding Site FreeLite assay on the SPAPlus. Clin Biochem. 2018;51:90–96.
   PubMed Web of Science ®Google Scholar
• Heaney JLJ, Campbell JP, Griffin AE, et al. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol. 2017;178(2):220–230.
   PubMed Web of Science ®Google Scholar
• Caillon H, Avet-Loiseau H, Attal M, et al. Comparison of sebia free light chain assay with freelite assay for the clinical management of diagnosis, response, and relapse assessment in multiple myeloma. Clin Lymph Myel Leuk. 2019;19(5):e228–e237.
   PubMed Web of Science ®Google Scholar
• Schneider N, Wynckel A, Kolb B, et al. Comparative analysis of immunoglobulin free light chains quantification by FreeliteTM (The Binding Site) and N Latex FLC (Siemens) methods. Ann Biol Clin (Paris). 2013;71:13–19.
   PubMed Web of Science ®Google Scholar
• Mollee P, Tate J, Pretorius CJ. Evaluation of the N latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med. 2013;51(12):2303–2310.
   PubMed Web of Science ®Google Scholar
• Bossuyt X, Delforge M, Reynders M, et al. Diagnostic thresholds for free light chains in multiple myeloma depend on the assay used. Leukemia. 2018;32(8):1815–1818.
   PubMed Web of Science ®Google Scholar
• Hutchison CA, Harding S, Hewins P, et al. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3(6):1684–1690.
   PubMed Web of Science ®Google Scholar
• Jacobs JFM, Hoedemakers RMJ, Teunissen E, et al. N latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med. 2014;52(6):853–859.
   PubMed Web of Science ®Google Scholar
• Kennard A, Hawley C, Tate J, et al. Comparison of Freelite™ and N latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis. Clin Chem Lab Med. 2016;54(6):1045–1052.
   PubMed Web of Science ®Google Scholar
• Tate JR, Hawley C, Mollee P. Response to article by Caponi et al. about serum free light chains. Clin Chem Lab Med. 2018;57(2):e1–e2.
   PubMed Web of Science ®Google Scholar
• Heaney JLJ, Campbell JP, Yadav P, et al. Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test. BMC Nephrol. 2017;18(1):247.
   PubMedGoogle Scholar
• Singh G. Serum free light chain assay and κ/λ Ratio: performance in patients with monoclonal gammopathy-high false negative rate for κ/λ ratio. J Clin Med Res. 2017;9(1):46–57.
   PubMedGoogle Scholar
• Jacobs JFM, Tate JR, Merlini G. Is accuracy of serum free light chain measurement achievable? Clin Chem Lab Med. 2016;54(6):1021–1030.
   PubMed Web of Science ®Google Scholar
• Schiffer M. Molecular anatomy and the pathological expression of antibody light chains. Am J Pathol. 1996;148(5):1339–1344.
   PubMed Web of Science ®Google Scholar
• Kaplan B, Golderman S, Aizenbud B, et al. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study. Am J Hematol. 2014;89(9):882–888.
   PubMed Web of Science ®Google Scholar
• Gatt ME, Kaplan B, Yogev D, et al. The use of serum free light chain dimerization patterns assist in the diagnosis of AL amyloidosis. Br J Haematol. 2018;182(1):86–92.
   PubMed Web of Science ®Google Scholar
• 510(k) FDA Premarket Notification (K150658): Optilite FreeLite Kappa Free Kit, Optilite Freelite Lambda Free Kit. 2015 [cited 2019 Sept 4]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K150658
   Google Scholar
• 510(k) FDA Premarket notification (K153394): Diazyme Laboratories kappa and lambda FLC. 2016 [cited 2019 Sept 4]. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K153394
   Google Scholar